CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals


Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells. The agreement gives Janssen Pharmaceuticals exclusive access to a selected portfolio of small molecules and biologics research programs.

The agreement between Evotec and Janssen triggers an upfront payment of US $8 million. Upon achievement of certain pre-clinical, clinical, regulatory and commercial goals, Janssen would make future milestone payments, of up to a total of about US $200 million to US $300 million per product. In addition, Janssen will pay royalties on future sales of any products that result from this collaboration. The upfront, milestone and royalty payments will be shared by Evotec and Harvard according to pre-agreed terms. Evotec will receive additional research support for discovery and early development work that will be conducted in collaboration with Janssen.

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242,